PT-2385 treatment also enhances the anti-metastatic activity of sorafenib by repressing HIF-2α-related Stat-3/Akt/Erk signaling in human hepatocellular carcinoma cells [181]. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.